XML 130 R2.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Pay vs Performance Disclosure - USD ($) | 5 Months Ended | 7 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2024 | Jan. 31, 2024 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2021
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  |  |  | ##### Pay vs. Performance As required by SEC rules, we are providing the following information about the relationship between executive compensation actually paid (as defined by SEC rules) and certain financial performance measures. For information about how our Compensation Committee seeks to align executive compensation with the Company’s performance, see “Compensation discussion and analysis.” The amounts in the table below are calculated in accordance with SEC rules and do not represent amounts actually earned or realized by our NEOs.
|  | Summary Compensation Table Total for |  |  | Compensation actually paid to |  |  | Summary Compensation Table Total for |  |  | Compensation actually paid to |  |  | Average Summary Compensation Table Total |  |  | Average Compensation actually paid |  |  | Value of Initial Fixed $100 Investment based on: |  |  |  |  |  | Company- selected Measure
Fiscal Year |  | CEO(1)(2) Mr. Kelderman |  |  | CEO(1)(2)(3) Mr. Kelderman |  |  | CEO(1) Mr. Kummeth |  |  | CEO(1)(3) Mr. Kummeth |  |  | for Non-PEO NEOs(2) |  |  | to Non-PEO NEOs(2) |  |  | Company TSR |  |  | Peer Group TSR(4) |  |  | Net Income(5) |  |  | (Organic Revenue)(6)
2024 |  | $ | 6,852,495 |  |  | $ | 3,403,621 |  |  | $ | 6,792,945 |  |  | $ | 4,821,823 |  |  | $ | 12,300,286 |  |  | $ | 4,147,638 |  |  | $ | 110.17 |  |  | $ | 131.47 |  |  | $ | 168,105,000 |  |  | $ | 1,141,700
2023 |  |  | 0 |  |  |  | 0 |  |  |  | 30,584,644 |  |  |  | 4,684,176 |  |  |  | 2,258,387 |  |  |  | 2,424,680 |  |  |  | 124.96 |  |  |  | 126.72 |  |  |  | 285,442,000 |  |  |  | 1,134,700
2022 |  |  | 0 |  |  |  | 0 |  |  |  | 15,370,549 |  |  |  | (6,349,624 | ) |  |  | 3,223,063 |  |  |  | (2,680,481 | ) |  |  | 132.17 |  |  |  | 129.72 |  |  |  | 263,099,000 |  |  |  | 1,113,600
2021 |  |  | 0 |  |  |  | 0 |  |  |  | 15,889,896 |  |  |  | 105,676,083 |  |  |  | 4,950,600 |  |  |  | 26,444,391 |  |  |  | 171.17 |  |  |  | 147.61 |  |  |  | 139,585,000 |  |  |  | 915,900
(1) | The Company had two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO for the full fiscal years 2021 through 2023.
(2) | For fiscal year 2024, Mr. Kelderman held his position as President, Diagnostics and Genomics prior to assuming the position of CEO on February 1, 2024. Therefore, any compensation granted or vested prior to assuming the position of CEO is included in the average non-PEO NEO compensation for fiscal year 2024.
(3) | Amounts reported in this column and in the table below represent the amount of “Compensation Actually Paid” or “CAP” as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the individual(s) during the applicable fiscal year. The following table summarizes the adjustments made to total compensation in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation Actually Paid”.
(4) | The Peer Group TSR in the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year 2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30, 2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
(5) | Net income represents “Net earnings, including noncontrolling interest” as reported in the Company’s Annual Report on Form 10-K.
(6) | Sales shown reflect organic revenue as calculated for purposes of our executive compensation program for the applicable reporting year. Refer to Appendix A for a reconciliation between GAAP and non-GAAP measures.
(1) | The Company had two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO for the full fiscal years 2021 through 2023.
(2) | For fiscal year 2024, Mr. Kelderman held his position as President, Diagnostics and Genomics prior to assuming the position of CEO on February 1, 2024. Therefore, any compensation granted or vested prior to assuming the position of CEO is included in the average non-PEO NEO compensation for fiscal year 2024.
(3) | Amounts reported in this column and in the table below represent the amount of “Compensation Actually Paid” or “CAP” as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the individual(s) during the applicable fiscal year. The following table summarizes the adjustments made to total compensation in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation Actually Paid”.
| For this purpose, the fair value of equity awards was determined pursuant to the FASB ASC Topic 718. Assumptions used in the calculation of the fair value are consistent with the stock option valuation model used to determine the amounts reported in the Company’s audited financial statements, included in the Company’s Annual Report on Form 10-K.
| The fair value of unvested time-based share awards, including restricted stock awards and restricted stock units, as well as the valuation of all share-based awards upon vesting, is based upon the closing price for a share of Bio-Techne common stock for the applicable date of measurement. The fair value of unvested performance share awards is based upon the probable outcome of the applicable performance conditions at the time of measurement. The fair value of unvested options, and the fair value received upon the vesting of stock options, is based upon the Black-Scholes option-pricing model as of the date of measurement, consistent with the stock option valuation model used to determine amounts reported in the Company’s Annual Report on Form 10-K.
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Total from Summary Compensation Table(i) |  |  | 6,852,495 |  |  |  | 6,792,945 |  |  |  | 12,300,286 |  |  |  | 30,584,644 |  |  |  | 2,258,387 |  |  |  | 15,370,549 |  |  |  | 3,223,063 |  |  |  | 15,889,896 |  |  |  | 4,950,600 |
| Subtract: Grant date fair value of option and stock awards granted in the fiscal year(ii) |  |  | (5,793,851 | ) |  |  | (5,000,028 | ) |  |  | (9,849,980 | ) |  |  | (29,325,210 | ) |  |  | (850,075 | ) |  |  | (10,299,362 | ) |  |  | (949,840 | ) |  |  | (11,199,803 |  |  |  | (1,722,395 | )
| Add: Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |  |  | 2,344,977 |  |  |  | 4,234,157 |  |  |  | 2,565,518 |  |  |  | 4,318,227 | (11) |  |  | 1,382,025 |  |  |  | 6,472,546 |  |  |  | 1,106,688 |  |  |  | 30,362,017 |  |  |  | 10,602,750 |
| Add/Subtract: Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |  |  | — |  |  |  | (1,241,718 | ) |  |  | (847,318 | ) |  |  | (6,132,401 | ) |  |  | (877,492 | ) |  |  | (22,021,635 | ) |  |  | (5,636,997 | ) |  |  | 64,935,446 |  |  |  | 11,789,651 |
| Add: Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
| Add/Subtract: Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year) of prior year awards that failed to vest(vi) |  |  | — |  |  |  | 36,468 |  |  |  | (20,867 | ) |  |  | 5,238,918 |  |  |  | 633,346 |  |  |  | 4,128,278 |  |  |  | 469,566 |  |  |  | 5,688,527 |  |  |  | 823,785 |
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Subtract: Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (121,511 | ) |  |  | — |  |  |  | (892,961 | ) |  |  | — |  |  |  | — |
| Compensation Actually Paid |  |  | 3,403,621 |  |  |  | 4,821,823 |  |  |  | 4,147,638 |  |  |  | 4,684,176 |  |  |  | 2,424,680 |  |  |  | (6,349,624 | ) |  |  | (2,680,481 | ) |  |  | 105,676,083 |  |  |  | 26,444,391 |
| (i) | Represents Total Compensation as reported in the Summary Compensation Table for each fiscal year
| (ii) | Represents Stock Awards and Option Awards from the Summary Compensation Table for each fiscal year
| (iii) | Represents the aggregate fair value as of each fiscal year-end of outstanding and unvested option and stock awards granted during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
| (iv) | Represents the aggregate change in fair value during each fiscal year of the outstanding and unvested option and stock awards granted in prior fiscal years and held as of the last day of the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
| (v) | Represents the aggregate fair value as of the vesting date of for each option and stock award that was granted and vested during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
| (vi) | Represents the aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option and stock award that was granted in a prior fiscal year and which vested during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
| (vii) | Represents the fair value as of the end of the prior fiscal year of option and stock awards that were granted in any prior fiscal year that failed to meet the applicable vesting conditions during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes. These options and stock awards relate to retirements during the applicable fiscal year.
(4) | The Peer Group TSR in the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year 2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30, 2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
(5) | Net income represents “Net earnings, including noncontrolling interest” as reported in the Company’s Annual Report on Form 10-K.
(6) | Sales shown reflect organic revenue as calculated for purposes of our executive compensation program for the applicable reporting year. Refer to Appendix A for a reconciliation between GAAP and non-GAAP measures.
(7) | The non-PEO NEOs during fiscal year 2024 were James Hippel, William Geist, Kim Kelderman (until February 1, 2024), Shane Bohnen, and Matthew McManus (from January 1, 2024 until the end of the fiscal year).
(8) | The non-PEO NEOs during fiscal year 2023 were James Hippel, William Geist, Kim Kelderman, Shane Bohnen, and Brenda Furlow.
(9) | The non-PEO NEOs during fiscal year 2022 were James Hippel, William Geist, Kim Kelderman, Brenda Furlow, and David Eansor.
(10) | The non-PEO NEOs during fiscal year 2021 were James Hippel, Kim Kelderman, Brenda Furlow, and David Eansor.
(11) | As of June 30, 2023, relates to the time-vesting restricted share units that were granted in fiscal year 2023. The threshold for the performance-vesting awards was not achieved.
Company Selected Measure Name |  |  |  | organic revenue |  |  |  |  |
Named Executive Officers, Footnote [Text Block] |  |  |  |
(1) | The Company had two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO for the full fiscal years 2021 through 2023.
Peer Group Issuers, Footnote |  |  |  | The Peer Group TSR in the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year 2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30, 2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. |  |  |  |  |
PEO Total Compensation Amount | [1] |  |  |  |  | $ 30,584,644 |  | $ 15,370,549 | $ 15,889,896
PEO Actually Paid Compensation Amount | [1] |  |  |  |  | 4,684,176 |  | (6,349,624) | 105,676,083
Adjustment To PEO Compensation, Footnote |  |  |  |
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Total from Summary Compensation Table(i) |  |  | 6,852,495 |  |  |  | 6,792,945 |  |  |  | 12,300,286 |  |  |  | 30,584,644 |  |  |  | 2,258,387 |  |  |  | 15,370,549 |  |  |  | 3,223,063 |  |  |  | 15,889,896 |  |  |  | 4,950,600 |
| Subtract: Grant date fair value of option and stock awards granted in the fiscal year(ii) |  |  | (5,793,851 | ) |  |  | (5,000,028 | ) |  |  | (9,849,980 | ) |  |  | (29,325,210 | ) |  |  | (850,075 | ) |  |  | (10,299,362 | ) |  |  | (949,840 | ) |  |  | (11,199,803 |  |  |  | (1,722,395 | )
| Add: Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |  |  | 2,344,977 |  |  |  | 4,234,157 |  |  |  | 2,565,518 |  |  |  | 4,318,227 | (11) |  |  | 1,382,025 |  |  |  | 6,472,546 |  |  |  | 1,106,688 |  |  |  | 30,362,017 |  |  |  | 10,602,750 |
| Add/Subtract: Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |  |  | — |  |  |  | (1,241,718 | ) |  |  | (847,318 | ) |  |  | (6,132,401 | ) |  |  | (877,492 | ) |  |  | (22,021,635 | ) |  |  | (5,636,997 | ) |  |  | 64,935,446 |  |  |  | 11,789,651 |
| Add: Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
| Add/Subtract: Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year) of prior year awards that failed to vest(vi) |  |  | — |  |  |  | 36,468 |  |  |  | (20,867 | ) |  |  | 5,238,918 |  |  |  | 633,346 |  |  |  | 4,128,278 |  |  |  | 469,566 |  |  |  | 5,688,527 |  |  |  | 823,785 |
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Subtract: Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (121,511 | ) |  |  | — |  |  |  | (892,961 | ) |  |  | — |  |  |  | — |
| Compensation Actually Paid |  |  | 3,403,621 |  |  |  | 4,821,823 |  |  |  | 4,147,638 |  |  |  | 4,684,176 |  |  |  | 2,424,680 |  |  |  | (6,349,624 | ) |  |  | (2,680,481 | ) |  |  | 105,676,083 |  |  |  | 26,444,391 |
Non-PEO NEO Average Total Compensation Amount | [1],[2] |  |  | $ 12,300,286 |  | 2,258,387 |  | 3,223,063 | 4,950,600
Non-PEO NEO Average Compensation Actually Paid Amount | [2] |  |  | $ 4,147,638 |  | 2,424,680 |  | (2,680,481) | 26,444,391
Adjustment to Non-PEO NEO Compensation Footnote |  |  |  |
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Total from Summary Compensation Table(i) |  |  | 6,852,495 |  |  |  | 6,792,945 |  |  |  | 12,300,286 |  |  |  | 30,584,644 |  |  |  | 2,258,387 |  |  |  | 15,370,549 |  |  |  | 3,223,063 |  |  |  | 15,889,896 |  |  |  | 4,950,600 |
| Subtract: Grant date fair value of option and stock awards granted in the fiscal year(ii) |  |  | (5,793,851 | ) |  |  | (5,000,028 | ) |  |  | (9,849,980 | ) |  |  | (29,325,210 | ) |  |  | (850,075 | ) |  |  | (10,299,362 | ) |  |  | (949,840 | ) |  |  | (11,199,803 |  |  |  | (1,722,395 | )
| Add: Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |  |  | 2,344,977 |  |  |  | 4,234,157 |  |  |  | 2,565,518 |  |  |  | 4,318,227 | (11) |  |  | 1,382,025 |  |  |  | 6,472,546 |  |  |  | 1,106,688 |  |  |  | 30,362,017 |  |  |  | 10,602,750 |
| Add/Subtract: Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |  |  | — |  |  |  | (1,241,718 | ) |  |  | (847,318 | ) |  |  | (6,132,401 | ) |  |  | (877,492 | ) |  |  | (22,021,635 | ) |  |  | (5,636,997 | ) |  |  | 64,935,446 |  |  |  | 11,789,651 |
| Add: Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
| Add/Subtract: Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year) of prior year awards that failed to vest(vi) |  |  | — |  |  |  | 36,468 |  |  |  | (20,867 | ) |  |  | 5,238,918 |  |  |  | 633,346 |  |  |  | 4,128,278 |  |  |  | 469,566 |  |  |  | 5,688,527 |  |  |  | 823,785 |
|  |  | FY24 |  | FY23 |  |  | FY22 |  | FY21 |
|  |  | CEO Mr. Kelderman |  |  | CEO Mr. Kummeth |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |  |  | CEO |  |  | Non-PEO NEOs |
| Subtract: Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (121,511 | ) |  |  | — |  |  |  | (892,961 | ) |  |  | — |  |  |  | — |
| Compensation Actually Paid |  |  | 3,403,621 |  |  |  | 4,821,823 |  |  |  | 4,147,638 |  |  |  | 4,684,176 |  |  |  | 2,424,680 |  |  |  | (6,349,624 | ) |  |  | (2,680,481 | ) |  |  | 105,676,083 |  |  |  | 26,444,391 |
Compensation Actually Paid vs. Total Shareholder Return |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Net Income |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  |  |  |  |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  |  |  |  |  |  |
Total Shareholder Return Amount |  |  |  | $ 110.17 |  | 124.96 |  | 132.17 | 171.17
Peer Group Total Shareholder Return Amount | [3] |  |  | 131.47 |  | 126.72 |  | 129.72 | 147.61
Net Income (Loss) Attributable to Parent | [4] |  |  | $ 168,105,000 |  | $ 285,442,000 |  | $ 263,099,000 | $ 139,585,000
Company Selected Measure Amount | [5] |  |  | 1,141,700 |  | 1,134,700 |  | 1,113,600 | 915,900
Measure [Axis]: 1 |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Measure Name |  |  |  | Organic Revenue Growth |  |  |  |  |
Measure [Axis]: 2 |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Measure Name |  |  |  | Adjusted Net Income |  |  |  |  |
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [6] |  |  | $ (9,849,980) |  | $ (850,075) |  | $ (949,840) | $ (1,722,395)
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [6] |  |  |  |  | (29,325,210) |  | (10,299,362) | (11,199,803)
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [7] |  |  | 2,565,518 |  | 1,382,025 |  | 1,106,688 | 10,602,750
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [7] |  |  |  |  | 4,318,227 | [8] | 6,472,546 | 30,362,017
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [9] |  |  | (847,318) |  | (877,492) |  | (5,636,997) | 11,789,651
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [9] |  |  |  |  | (6,132,401) |  | (22,021,635) | 64,935,446
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [10] |  |  |  |  |  |  |  |
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [10] |  |  |  |  |  |  |  |
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [11] |  |  | (20,867) |  | 633,346 |  | 469,566 | 823,785
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [11] |  |  |  |  | 5,238,918 |  | 4,128,278 | 5,688,527
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] | Non-PEO NEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [12] |  |  |  |  | (121,511) |  | (892,961) |
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] | PEO [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [12] |  |  |  |  |  |  |  |
Mr Kelderman [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount | [2],[13] |  |  | 6,852,495 | [1] | 0 |  | 0 | 0
PEO Actually Paid Compensation Amount | [2],[13],[14] |  |  | 3,403,621 | [1] | 0 |  | 0 | 0
PEO Name |  | Mr. Kelderman |  |  |  |  |  |  |
Mr Kelderman [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [6] |  |  | (5,793,851) |  |  |  |  |
Mr Kelderman [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [7] |  |  | 2,344,977 |  |  |  |  |
Mr Kelderman [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [9] |  |  |  |  |  |  |  |
Mr Kelderman [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [10] |  |  |  |  |  |  |  |
Mr Kelderman [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [11] |  |  |  |  |  |  |  |
Mr Kelderman [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [12] |  |  |  |  |  |  |  |
Mr Kummeth [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount | [13] |  |  | 6,792,945 | [1] | 30,584,644 |  | 15,370,549 | 15,889,896
PEO Actually Paid Compensation Amount | [13],[14] |  |  | 4,821,823 | [1] | $ 4,684,176 |  | $ (6,349,624) | $ 105,676,083
PEO Name |  |  | Mr. Kummeth |  |  | Mr. Kummeth |  | Mr. Kummeth | Mr. Kummeth
Mr Kummeth [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [6] |  |  | (5,000,028) |  |  |  |  |
Mr Kummeth [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [7] |  |  | 4,234,157 |  |  |  |  |
Mr Kummeth [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [9] |  |  | (1,241,718) |  |  |  |  |
Mr Kummeth [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [10] |  |  |  |  |  |  |  |
Mr Kummeth [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [11] |  |  | 36,468 |  |  |  |  |
Mr Kummeth [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | [12] |  |  |  |  |  |  |  |
[1] | Represents Total Compensation as reported in the Summary Compensation Table for each fiscal year
[2] | For fiscal year 2024, Mr. Kelderman held his position as President, Diagnostics and Genomics prior to assuming the position of CEO on February 1, 2024. Therefore, any compensation granted or vested prior to assuming the position of CEO is included in the average non-PEO NEO compensation for fiscal year 2024.
[3] | The Peer Group TSR in the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year 2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30, 2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
[4] | Net income represents “Net earnings, including noncontrolling interest” as reported in the Company’s Annual Report on Form 10-K.
[5] | Sales shown reflect organic revenue as calculated for purposes of our executive compensation program for the applicable reporting year. Refer to Appendix A for a reconciliation between GAAP and non-GAAP measures.
[6] | Represents Stock Awards and Option Awards from the Summary Compensation Table for each fiscal year
[7] | Represents the aggregate fair value as of each fiscal year-end of outstanding and unvested option and stock awards granted during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
[8] | As of June 30, 2023, relates to the time-vesting restricted share units that were granted in fiscal year 2023. The threshold for the performance-vesting awards was not achieved.
[9] | Represents the aggregate change in fair value during each fiscal year of the outstanding and unvested option and stock awards granted in prior fiscal years and held as of the last day of the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
[10] | Represents the aggregate fair value as of the vesting date of for each option and stock award that was granted and vested during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
[11] | Represents the aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option and stock award that was granted in a prior fiscal year and which vested during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes.
[12] | Represents the fair value as of the end of the prior fiscal year of option and stock awards that were granted in any prior fiscal year that failed to meet the applicable vesting conditions during the covered fiscal year, computed in accordance with the Company’s methodology used for financial reporting purposes. These options and stock awards relate to retirements during the applicable fiscal year.
[13] | The Company had two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO for the full fiscal years 2021 through 2023.
[14] | Amounts reported in this column and in the table below represent the amount of “Compensation Actually Paid” or “CAP” as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the individual(s) during the applicable fiscal year. The following table summarizes the adjustments made to total compensation in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation Actually Paid”.

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=tech_MrKeldermanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=tech_MrKummethMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |